Novartis AG

SWX:NOVN Stock Report

Market Cap: CHF 182.4b

Novartis Past Earnings Performance

Past criteria checks 5/6

Novartis has been growing earnings at an average annual rate of 4.6%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been declining at an average rate of 1.4% per year. Novartis's return on equity is 27.1%, and it has net margins of 23.6%.

Key information

4.6%

Earnings growth rate

6.7%

EPS growth rate

Pharmaceuticals Industry Growth16.3%
Revenue growth rate-1.4%
Return on equity27.1%
Net Margin23.6%
Next Earnings Update31 Jan 2025

Recent past performance updates

We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative

Nov 05
We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative

Recent updates

We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative

Nov 05
We Think Novartis' (VTX:NOVN) Robust Earnings Are Conservative

Investors Interested In Novartis AG's (VTX:NOVN) Earnings

Oct 21
Investors Interested In Novartis AG's (VTX:NOVN) Earnings

Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Sep 04
Novartis (VTX:NOVN) Has A Rock Solid Balance Sheet

Novartis AG's (VTX:NOVN) Price In Tune With Earnings

Mar 12
Novartis AG's (VTX:NOVN) Price In Tune With Earnings

Novartis (VTX:NOVN) Has Announced A Dividend Of $3.30

Feb 20
Novartis (VTX:NOVN) Has Announced A Dividend Of $3.30

Is There An Opportunity With Novartis AG's (VTX:NOVN) 47% Undervaluation?

Jan 04
Is There An Opportunity With Novartis AG's (VTX:NOVN) 47% Undervaluation?

Revenue & Expenses Breakdown

How Novartis makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SWX:NOVN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2449,94011,76112,4797,146
30 Jun 2448,86010,08312,4378,689
31 Mar 2447,7339,10712,4388,673
31 Dec 2346,6608,56812,4899,011
30 Sep 2345,8507,24512,20610,273
30 Jun 2344,5417,06212,0518,890
31 Mar 2341,6945,97611,5228,680
31 Dec 2243,4616,04912,1438,425
30 Sep 2246,01721,04212,9248,975
30 Jun 2248,60122,47213,6068,813
31 Mar 2252,99724,18414,7989,119
31 Dec 2143,97422,90812,7568,259
30 Sep 2152,3859,80714,7219,032
30 Jun 2151,5568,98414,5228,798
31 Mar 2149,8847,95514,1368,839
31 Dec 2049,8988,07214,1978,980
30 Sep 2049,5847,10314,1288,534
30 Jun 2049,5287,21014,2588,587
31 Mar 2049,9307,45114,4758,197
31 Dec 1948,6777,14214,3699,402
30 Sep 1947,8587,23814,1148,627
30 Jun 1946,7627,07713,8268,575
31 Mar 1946,39112,69713,7368,650
31 Dec 1846,09912,79713,7178,489
30 Sep 1847,36613,55214,0848,295
30 Jun 1848,67213,75214,5018,387
31 Mar 1849,5138,00414,8128,323
31 Dec 1743,4047,49912,4687,995
30 Sep 1749,5276,68414,7138,460
30 Jun 1749,1766,54314,4358,445
31 Mar 1749,3616,36714,2788,573
31 Dec 1649,3866,71214,1118,445
30 Sep 1649,6066,80714,1108,773
30 Jun 1649,7506,67214,1738,739
31 Mar 1649,9676,72214,1418,755
31 Dec 1550,3877,01714,2478,935
30 Sep 1550,6358,41714,2418,685
30 Jun 1551,4509,69714,3438,656
31 Mar 1552,50310,53614,5528,628
31 Dec 1453,63410,65714,9939,086
30 Sep 1453,90810,19115,1228,910
30 Jun 1453,5149,23315,2318,965
31 Mar 1452,8459,09515,1899,034
31 Dec 1352,7169,19215,1898,946

Quality Earnings: NOVN has a large one-off loss of $4.9B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: NOVN's current net profit margins (23.6%) are higher than last year (15.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: NOVN's earnings have grown by 4.6% per year over the past 5 years.

Accelerating Growth: NOVN's earnings growth over the past year (62.3%) exceeds its 5-year average (4.6% per year).

Earnings vs Industry: NOVN earnings growth over the past year (62.3%) exceeded the Pharmaceuticals industry 10.2%.

Return on Equity

High ROE: NOVN's Return on Equity (27.1%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y